[144] Zimmer Biomet Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Zimmer Biomet reports a proposed sale of 7,500 common shares through Fidelity Brokerage on the NYSE, with an aggregate market value of $766,708.20, scheduled for 08/13/2025. The filing lists 198,095,984 shares outstanding and shows the securities to be sold were acquired through employee programs: small ESPP purchases on 12/29/2023 (25), 06/28/2024 (28) and 12/31/2024 (29), and restricted stock vesting on 02/18/2025 (5,911) and 02/20/2025 (1,507). The filer reports Nothing to Report for sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Clear disclosure of proposed sale quantity (7,500 shares) and aggregate market value ($766,708.20)
• Source of shares documented: ESPP purchases and restricted stock vesting with specific acquisition dates and amounts
• No sales reported in the prior three months ("Nothing to Report"), indicating this filing records a discrete proposed sale

Negative

• None.

Insights

Securities Analyst

TL;DR: Proposed sale appears to be a routine, compensation-linked disposition with limited market impact based on the disclosed size and sourcing.

The filer plans to offer 7,500 shares via Fidelity with an aggregate market value shown as $766,708.20. The detailed acquisition lines identify the shares as coming from an ESPP and recent restricted stock vesting, indicating these are compensation-related holdings rather than an outright purchase from a third party. The form also reports no securities sold in the prior three months, which suggests this filing documents a discrete proposed sale. From an investor-analysis perspective, the disclosure is transparent and provides clear traceability of the lot origins, but the filing does not identify the seller by name within the provided content.

Corporate Governance / Compliance Specialist

TL;DR: Filing follows Rule 144 disclosure format and includes the standard attestation about material nonpublic information and trading-plan references.

The notice contains the customary representation that the person for whose account the securities will be sold does not know of material adverse information not publicly disclosed, and it references trading-plan adoption language where applicable. The broker is identified as Fidelity Brokerage Services LLC and the intended exchange is the NYSE. The filing records the dates and nature of acquisition (ESPP purchases and restricted stock vesting), which supports compliance with Rule 144 requirements on provenance of shares. There is no material adverse disclosure or indication of regulatory issues in the provided content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	7500	766708.20	198095984	08/13/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/29/2023	ESPP Purchase	Issuer			25	12/29/2023	Cash
Common	06/28/2024	ESPP Purchase	Issuer			28	06/28/2024	Cash
Common	12/31/2024	ESPP Purchase	Issuer			29	12/31/2024	Cash
Common	02/18/2025	Restricted Stock Vesting	Issuer			5911	02/18/2025	Compensation
Common	02/20/2025	Restricted Stock Vesting	Issuer			1507	02/20/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Zimmer Biomet (ZBH) Form 144 report?

The form reports a proposed sale of 7,500 common shares through Fidelity Brokerage on the NYSE with an aggregate market value of $766,708.20, scheduled for 08/13/2025.

How were the shares to be sold acquired?

The filing shows the shares were acquired via ESPP purchases on 12/29/2023 (25), 06/28/2024 (28) and 12/31/2024 (29), and via restricted stock vesting on 02/18/2025 (5,911) and 02/20/2025 (1,507).

Has the filer sold any ZBH securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Which broker and exchange are identified for the proposed sale?

The broker listed is Fidelity Brokerage Services LLC (900 Salem Street, Smithfield RI) and the named exchange is the NYSE.

Does the filing address material nonpublic information or trading plans?

Yes, the notice includes the standard representation that the seller does not know of any material adverse information not publicly disclosed and references trading-plan adoption language where applicable.